Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
7
88%
Ph phase_2
1
13%

Phase Distribution

7

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
Phase 2Efficacy & side effects
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (87.5%)
Phase 21 (12.5%)

Trials by Status

completed675%
terminated225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

NCT00952588
completedphase_1

AZD1152 in Diffuse Large B-cell Lymphoma

NCT01354392
completedphase_1

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

NCT00926731
completedphase_1

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

NCT00497991
completedphase_1

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

NCT01019161
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00952588Phase 2

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

Completed
NCT01354392Phase 1

AZD1152 in Diffuse Large B-cell Lymphoma

Completed
NCT00926731Phase 1

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Completed
NCT00497991Phase 1

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Completed
NCT01019161Phase 1

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Completed
NCT00530699Phase 1

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Completed
NCT00497731Phase 1

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Terminated
NCT00497679Phase 1

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8